S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
Senate rules referee weakens Dem drug plan in economic bill
Dems push Biden climate, health priorities toward Senate OK
China July exports rise, with trade surplus at record-high
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
Senate rules referee weakens Dem drug plan in economic bill
Dems push Biden climate, health priorities toward Senate OK
China July exports rise, with trade surplus at record-high
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
Senate rules referee weakens Dem drug plan in economic bill
Dems push Biden climate, health priorities toward Senate OK
China July exports rise, with trade surplus at record-high
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
Senate rules referee weakens Dem drug plan in economic bill
Dems push Biden climate, health priorities toward Senate OK
China July exports rise, with trade surplus at record-high
NYSE:EW

Edwards Lifesciences (EW) Stock Forecast, Price & News

$106.12
+1.27 (+1.21%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$103.47
$106.26
50-Day Range
$86.50
$107.29
52-Week Range
$85.58
$131.73
Volume
2.03 million shs
Average Volume
2.48 million shs
Market Capitalization
$65.79 billion
P/E Ratio
45.94
Dividend Yield
N/A
Price Target
$125.90

Edwards Lifesciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
18.6% Upside
$125.90 Price Target
Short Interest
Healthy
1.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
-0.09mentions of Edwards Lifesciences in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$11.44 M Sold Last Quarter
Proj. Earnings Growth
8.37%
From $2.51 to $2.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

72nd out of 1,283 stocks

Surgical Appliances & Supplies Industry

5th out of 25 stocks

Edwards Lifesciences logo

About Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $1.27 during trading on Friday, reaching $106.12. 2,033,510 shares of the company's stock traded hands, compared to its average volume of 2,478,073. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.37 and a quick ratio of 2.60. Edwards Lifesciences has a 12 month low of $85.58 and a 12 month high of $131.73. The company has a 50 day moving average of $97.35 and a 200-day moving average of $105.27. The stock has a market capitalization of $65.79 billion, a P/E ratio of 45.94, a price-to-earnings-growth ratio of 3.09 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Rating) last posted its earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.64 by ($0.01). The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The company's revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 earnings per share. On average, equities analysts expect that Edwards Lifesciences will post 2.51 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Cowen reduced their target price on shares of Edwards Lifesciences from $140.00 to $125.00 in a report on Monday, July 11th. Canaccord Genuity Group downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating and dropped their price target for the stock from $115.00 to $106.00 in a research note on Friday, July 29th. Stifel Nicolaus dropped their price target on shares of Edwards Lifesciences from $128.00 to $115.00 in a research note on Monday, July 18th. StockNews.com raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Friday. Finally, Truist Financial dropped their price target on shares of Edwards Lifesciences from $140.00 to $120.00 and set a "buy" rating on the stock in a research note on Wednesday, July 20th. Three research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $126.19.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Bernard J. Zovighian sold 4,811 shares of the business's stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $103.66, for a total transaction of $498,708.26. Following the completion of the transaction, the vice president now directly owns 21,247 shares of the company's stock, valued at approximately $2,202,464.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Daveen Chopra sold 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $102.49, for a total value of $102,490.00. Following the completion of the sale, the vice president now directly owns 18,911 shares of the company's stock, valued at approximately $1,938,188.39. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Bernard J. Zovighian sold 4,811 shares of the company's stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $103.66, for a total transaction of $498,708.26. Following the completion of the sale, the vice president now directly owns 21,247 shares of the company's stock, valued at $2,202,464.02. The disclosure for this sale can be found here. Insiders sold 120,854 shares of company stock valued at $11,439,096 in the last ninety days. Company insiders own 1.29% of the company's stock.

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

Edwards Lifesciences Corp. Q2 Profit Decreases, misses estimates
EW June 2023 Options Begin Trading
Edwards Lifesciences (NYSE:EW) Price Target Cut to $120.00
See More Headlines

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Company Calendar

Last Earnings
7/28/2022
Today
8/07/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
15,700
Year Founded
1958

Price Target and Rating

Average Stock Price Forecast
$125.90
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$106.00
Forecasted Upside/Downside
+18.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
20 Analysts

Profitability

Net Income
$1.50 billion
Pretax Margin
31.15%

Debt

Sales & Book Value

Annual Sales
$5.23 billion
Cash Flow
$2.46 per share
Book Value
$9.59 per share

Miscellaneous

Free Float
611,946,000
Market Cap
$65.79 billion
Optionable
Optionable
Beta
1.12

Social Links















EW Stock - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences
or view top-rated stocks.

What is Edwards Lifesciences' stock price forecast for 2022?

20 analysts have issued 12-month price targets for Edwards Lifesciences' stock. Their EW stock forecasts range from $106.00 to $144.00. On average, they anticipate Edwards Lifesciences' share price to reach $125.90 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price.
View analysts' price targets for Edwards Lifesciences
or view top-rated stocks among Wall Street analysts.

How has Edwards Lifesciences' stock performed in 2022?

Edwards Lifesciences' stock was trading at $129.55 at the beginning of 2022. Since then, EW stock has decreased by 18.1% and is now trading at $106.12.
View the best growth stocks for 2022 here
.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our earnings forecast for Edwards Lifesciences
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings data on Thursday, July, 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by $0.01. The medical research company had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 24.77% and a net margin of 27.18%. Edwards Lifesciences's quarterly revenue was down .2% on a year-over-year basis. During the same period in the previous year, the business earned $0.64 earnings per share.
Read Edwards Lifesciences' conference call transcript
.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences shares split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were payable to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $2.50-$2.50 for the period, compared to the consensus earnings per share estimate of $2.56. The company issued revenue guidance of $5.35 billion-$5.55 billion, compared to the consensus revenue estimate of $5.71 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of Nova Scotia (93.89%), Brown Advisory Inc. (2.57%), Sumitomo Mitsui Trust Holdings Inc. (0.43%), Allspring Global Investments Holdings LLC (0.40%), CIBC Private Wealth Group LLC (0.32%) and KBC Group NV (0.16%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, Scott B Ullem and William J Phd Link.
View institutional ownership trends for Edwards Lifesciences
.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $106.12.

How much money does Edwards Lifesciences make?

Edwards Lifesciences (NYSE:EW) has a market capitalization of $65.79 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.31 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

Edwards Lifesciences employs 15,700 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More

When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for Edwards Lifesciences is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.

This page (NYSE:EW) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.